Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Volume 1833, Issue 1, Pages 101-109Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbamcr.2012.10.021
Keywords
RAGE; Inflammation; Cancer; Tissue regeneration/repair; HMGB1; S100 protein
Categories
Funding
- Ministero dell'Universita e della Ricerca [PRIN 2007LNKSYS, 2007AWZTHH_004, 2009WBFZYM_002]
- Association Francaise contre les Myopathies [12992]
- Associazione Italiana per la Ricerca sul Cancro [6021]
- Fondazione Cassa di Risparmio di Perugia [2007.0218.020, 2009.020.0021]
Ask authors/readers for more resources
RAGE (receptor for advanced glycation end-products) is a multiligand receptor of the immunoglobulin superfamily involved in inflammation, diabetes, atherosclerosis, nephropathy, neurodegeneration, and cancer. Advanced glycation end-products, high mobility group box-1 (amphoterin), beta-amyloid fibrils, certain S100 proteins, and DNA and RNA are RAGE ligands. Upon RAGE ligation, adaptor proteins (i.e., diaphanous-1, TIRAP, MyD88 and/or other as yet unidentified adaptors) associate with RAGE cytoplasmic domain resulting in signaling. However, RAGE activation may not be restricted to pathological statuses, the receptor being involved in tissue homeostasis and regeneration/repair upon acute injury, and in resolution of inflammation. RAGE effects are strongly dependent on the cell type and the context, which may condition therapeutic strategies aimed at reducing RAGE signaling. (c) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available